In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...